Ballard CG, Morris CM, Rao H, O'Brien JT, Barber R, Stephens S, Rowan EN, Gibson A, Kalaria RN, Kenny RA (2004). APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology. 63: 1399-1402.
Liberman JN, Stewart WF, Wesnes KA, Troncoso J (2002). Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. The Journal of Neurology. 58: 1038-1044.
O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA, O'Brien JT, Swan AG, Fairbairn AF, Wesnes KA, del Ser T, Edwardson JA, Morris CM, McKeith IG (2003). Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics. 13: 231-239.
Pomara N, Willoughby L, Wesnes KA, Greenblatt DJ, Sidtis JJ (2005). Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults. Archives of General Psychiatry. 62: 209-216.
Pomara N, Willoughby LM, Hashim A, Sershen H, Sidtis JJ, Wesnes KA, Greenblatt DJ Lajtha A (2004). Effects of acute lorazepam administration on aminergic activity in normal elderly subjects: relationship to performance effects and apolipoprotein genotype. Neurochemical Research. 29: 1391-1398.
Pomara N, Willoughby LM, Wesnes KA, Sidtis JJ (2004). Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study. Neuropsychopharmacology. 29: 403-409.
Rowan EN, Morris CM, Stephens S, Ballard CG, Dickinson H, Rao H, Saxby BK, McLaren AT, Kalaria RN, Kenny RA (2005). Impact of hypertension and apolipoprotein E4 on post-stroke cognition in subjects >75 years of age. Stroke. 36: 1864-1868.